Ireland - English - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - brimonidine tartrate; timolol maleate - eye drops, solution - 2 mg/ml + 5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - brimonidine tartrate; timolol maleate - eye drops, solution - beta blocking agents1); timolol, combinations

United States - English - NLM (National Library of Medicine)

a-s medication solutions - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. this loss of effect appears with a variable time of onset in each patient and should be closely monitored. brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [see adverse reactions (6.1) and (6.2)]. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5 mg/kg/day) achieved auc exposure values 375-fold higher or 19-fold higher, respectively, than similar values estimated in humans treated with brim

United States - English - NLM (National Library of Medicine)

a-s medication solutions - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution, 0.2% is indicated for lowering intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. this loss of effect appears with a variable time of onset in each patient and should be closely monitored. brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years) [see use in specific populations (8.4)]. brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [see adverse reactions (6.1) and (6.2)]. teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5 mg/kg/day) achi

United States - English - NLM (National Library of Medicine)

a-s medication solutions - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. this loss of effect appears with a variable time of onset in each patient and should be closely monitored. brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years) [see  use  in  specific  populations  (8.4) ].   brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [see  adverse  reactions  (6.1)  and  (6.2) ]. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - brimonidine tartrate and timolol maleate ophthalmic solution 0.2% /0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see warnings and precautions (5.1, 5.3)] . brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals limited - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - brimonidine tartrate and timolol maleate ophthalmic solution 0.2% /0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see warnings and precautions (5.1, 5.3)] . brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - brimonidine tartrate 2 mg/ml - eq. brimonidine 1,3 mg/ml; timolol maleate 6,8 mg/ml - eq. timolol 5 mg/ml - eye drops, solution - 2 mg/ml - 5 mg/ml - brimonidine tartrate 2 mg/ml; timolol maleate 6.8 mg/ml - timolol

Kenya - English - Pharmacy and Poisons Board

brimonidine tartrate & timolol maleate - ophthalmic solution - brimonidine tartrate 0.2%w/v & timolol maleate… - brimonidine

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml - eye drops, solution - excipient ingredients: polyvinyl alcohol; benzalkonium chloride; citric acid; hydrochloric acid; sodium citrate dihydrate; sodium chloride; sodium hydroxide; purified water - indications:enidin eye drops are effective as monotherapy for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension in whom (beta symbol)-blockers are not tolerated or are contraindicated. indications as at 7 december 1999: enidin eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension.enidin eye drops can be used in the treatment of glaucoma either as monotherapy or in combination with topical beta-blockers.